Search Results - "FEDORAK, R"

Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study by Kelly, C. P., Green, P. H. R., Murray, J. A., DiMarino, A., Colatrella, A., Leffler, D. A., Alexander, T., Arsenescu, R., Leon, F., Jiang, J. G., Arterburn, L. A., Paterson, B. M., Fedorak, R. N.

“…Summary Background Coeliac disease, an autoimmune disorder triggered by gluten ingestion, is managed by a gluten‐free diet (GFD), which is difficult for many…”
Get full text

The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti‐TNF use: a time‐trend study by Reich, K. M., Chang, H.‐J., Rezaie, A., Wang, H., Goodman, K. J., Kaplan, G. G., Svenson, L. W., Lees, G., Fedorak, R. N., Kroeker, K. I.

“…Summary Background Medical therapy is standard treatment for ulcerative colitis with colectomy reserved for medically refractory disease or malignancy. The…”
Get full text

Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort by Gies, N., Kroeker, K. I., Wong, K., Fedorak, R. N.

“…Aliment Pharmacol Ther 2010; 32: 522–528 Summary Background  Randomized, controlled trials have demonstrated that anti‐TNF agents are efficacious in inducing…”
Get full text

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort by Ma, C., Fedorak, R. N., Kaplan, G. G., Dieleman, L. A., Devlin, S. M., Stern, N., Kroeker, K. I., Seow, C. H., Leung, Y., Novak, K. L., Halloran, B. P., Huang, V. W., Wong, K., Blustein, P. K., Ghosh, S., Panaccione, R.

“…Summary Background Ustekinumab is a monoclonal antibody targeting interleukins‐12 and ‐23, with efficacy in Crohn's disease (CD) demonstrated in clinical…”
Get full text

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease by Ma, C., Huang, V., Fedorak, D. K., Kroeker, K. I., Dieleman, L. A., Halloran, B. P., Fedorak, R. N.

“…Summary Background The efficacy of adalimumab in maintaining remission in Crohn's disease patients may wane over time, leading to secondary loss of response…”
Get full text

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease by Khanna, R., Sattin, B. D., Afif, W., Benchimol, E. I., Bernard, E.‐J., Bitton, A., Bressler, B., Fedorak, R. N., Ghosh, S., Greenberg, G. R., Marshall, J. K., Panaccione, R., Seidman, E. G., Silverberg, M. S., Steinhart, A. H., Sy, R., Van Assche, G., Walters, T. D., Sandborn, W. J., Feagan, B. G.

“…Summary Background Tumour necrosis factor (TNF)‐antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however,…”
Get full text

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease by Feagan, B. G., Sandborn, W. J., D'Haens, G., Lee, S. D., Allez, M., Fedorak, R. N., Seidler, U., Vermeire, S., Lawrance, I. C., Maroney, A. C., Jurgensen, C. H., Heath, A., Chang, D. J.

“…Summary Background Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatments. Aims To conduct…”
Get full text

Prevalence of Epstein–Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study by Linton, M. S., Kroeker, K., Fedorak, D., Dieleman, L., Fedorak, R. N.

“…Summary Background The Epstein–Barr Virus (EBV) is truly prolific, with a prevalence of more than 90% in the adult human population. There are, however, little…”
Get full text

Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis by Ma, C., Guizzetti, L., Panaccione, R., Fedorak, R. N., Pai, R. K., Parker, C. E., Nguyen, T. M., Khanna, R., Vande Casteele, N., D'Haens, G., Sandborn, W. J., Feagan, B. G., Jairath, V.

“…Summary Background Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and…”
Get full text

Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort by Waugh, A. W. G., Garg, S., Matic, K., Gramlich, L., Wong, C., Sadowski, D. C., Millan, M., Bailey, R., Todoruk, D., Cherry, R., Teshima, C. W., Dieleman, L., Fedorak, R. N.

“…Aliment Pharmacol Ther 2010; 32: 1129–1134 Summary Background  Tumour necrosis factor‐blockade with infliximab has advanced the treatment of Crohn’s disease…”
Get full text

A one‐hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study by Lee, T. W., Singh, R., Fedorak, R. N.

“…Aliment Pharmacol Ther 2011; 34: 181–187 Summary Background  Infliximab is a chimeric monoclonal antibody to tumour necrosis factor alpha (TNFα) with efficacy…”
Get full text

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice by Madsen, Karen L., Doyle ‡, Jason S., Jewell ‡, Laurence D., Tavernini, Michele M., Fedorak, Richard N.

“…Background & Aims: Intestinal luminal microflora, or their products, are likely an important initiating factor in the pathogenesis of inflammatory bowel…”
Get full text

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study by Valentine, J F, Fedorak, R N, Feagan, B, Fredlund, P, Schmitt, R, Ni, P, Humphries, T J

“…Although treatment with corticosteroids induces remission in Crohn's disease, prolonged exposure to corticosteroids is undesirable. This randomised clinical…”
Get more information

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial by Sandborn, W J, Hanauer, S B, Rutgeerts, P, Fedorak, R N, Lukas, M, MacIntosh, D G, Panaccione, R, Wolf, D, Kent, J D, Bittle, B, Li, J, Pollack, P F

“…Background: Adalimumab induced clinical remission after four weeks in patients with active Crohn’s disease in the CLASSIC I trial. Objective: To evaluate long…”
Get full text

Multiple doses of intravenous Interleukin 10 in steroid-refractory Crohn's disease by VAN DEVENTER, S. J. H, ELSON, C. O, FEDORAK, R. N

Get full text

A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease by Feagan, Brian G, Fedorak, Richard N, Irvine, E. Jan, Wild, Gary, Sutherland, Lloyd, Steinhart, A. Hillary, Greenberg, Gordon R, Koval, John, Wong, Cindy J, Hopkins, Marybeth, Hanauer, Stephen B, McDonald, John W.D

“…Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract. Since the cause of the disease is unknown, 1 – 4 nonspecific antiinflammatory…”
Get full text

imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens by Sydora, B.C, MacFarlane, S.M, Lupicki, M, Dmytrash, A.L, Dieleman, L.A, Fedorak, R.N

“…Intestinal microflora play a critical role in the initiation and perpetuation of chronic inflammatory bowel diseases. In genetically susceptible hosts,…”
Get full text

Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial by VAN RENSBURG, C., BARKUN, A. N., RACZ, I., FEDORAK, R., BORNMAN, P. C., BEGLINGER, C., BALANZÓ, J., DEVIÈRE, J., KUPCINSKAS, L., LUEHMANN, R., DOERFLER, H., SCHÄFER‐PREUSS, S.

“…Summary Background  Controlled pantoprazole data in peptic ulcer bleeding are few. Aim  To compare intravenous (IV) pantoprazole with IV ranitidine for…”
Get full text

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease by Sandborn, William J., Tremaine, William J., Wolf, Douglas C., Targan, Stephan R., Sninsky, Charles A., Sutherland, Lloyd R., Hanauer, Stephen B., McDonald, John W.D., Feagan, Brian G., Fedorak, Richard N., Isaacs, Kim L., Pike, M.Gennette, Mays, Dennis C., Lipsky, James J., Gordon, Susan, Kleoudis, Christi S., Murdock, Robert H.

“…Background & Aims: Azathioprine is effective for Crohn's disease but acts slowly. A loading dose may decrease the time to response. Methods: A…”
Get full text

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease by Sands, Bruce E, Anderson, Frank H, Bernstein, Charles N, Chey, William Y, Feagan, Brian G, Fedorak, Richard N, Kamm, Michael A, Korzenik, Joshua R, Lashner, Bret A, Onken, Jane E, Rachmilewitz, Daniel, Rutgeerts, Paul, Wild, Gary, Wolf, Douglas C, Marsters, Paul A, Travers, Suzanne B, Blank, Marion A, van Deventer, Sander J

“…Infliximab, a monoclonal antibody against tumor necrosis factor, reduces disease activity in patients with Crohn's disease. In this study of patients with…”
Get full text